Login / Signup

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.

Charu SabharwalVani SundaraiyerYahong PengLisa MoyerTodd J BelangerBradford D GessnerLuis JodarKathrin U JansenWilliam C GruberDaniel A ScottWendy Watson
Published in: Human vaccines & immunotherapeutics (2022)
NCT03760146, NCT03828617.
Keyphrases
  • healthcare
  • cancer therapy